Literature DB >> 16879083

Idiosyncratic drug reactions: current understanding.

Jack Uetrecht1.   

Abstract

Clinical characteristics and circumstantial evidence suggest that idiosyncratic drug reactions are caused by reactive metabolites and are immune-mediated; however, there are few definitive data and there are likely exceptions. There are three principal hypotheses for how reactive metabolites might induce an immune-mediated idiosyncratic reaction: the hapten hypothesis, the danger hypothesis, and the PI hypothesis. It has been proposed that some idiosyncratic reactions, especially those involving the liver, represent metabolic idiosyncrasy; however, there are even less data to support this hypothesis. The unpredictable nature of these reactions makes mechanistic studies difficult. There is a very strong association with specific human leukocyte antigen (HLA) genes for certain reactions, but this has only been demonstrated for very few drugs. Animal models represent a very powerful tool for mechanistic studies, but the number of valid models is also limited. There may be biomarkers of risk; however, much more work needs to be done.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 16879083     DOI: 10.1146/annurev.pharmtox.47.120505.105150

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  67 in total

1.  Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire.

Authors:  David A Ostrov; Barry J Grant; Yuri A Pompeu; John Sidney; Mikkel Harndahl; Scott Southwood; Carla Oseroff; Shun Lu; Jean Jakoncic; Cesar Augusto F de Oliveira; Lun Yang; Hu Mei; Leming Shi; Jeffrey Shabanowitz; A Michelle English; Amanda Wriston; Andrew Lucas; Elizabeth Phillips; Simon Mallal; Howard M Grey; Alessandro Sette; Donald F Hunt; Soren Buus; Bjoern Peters
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-29       Impact factor: 11.205

Review 2.  Mechanisms of drug toxicity and relevance to pharmaceutical development.

Authors:  F Peter Guengerich
Journal:  Drug Metab Pharmacokinet       Date:  2010-10-22       Impact factor: 3.614

3.  Editor's Highlight: An Impaired Immune Tolerance Animal Model Distinguishes the Potential of Troglitazone/Pioglitazone and Tolcapone/Entacapone to Cause IDILI.

Authors:  Alastair Mak; Ryuji Kato; Kyle Weston; Anthony Hayes; Jack Uetrecht
Journal:  Toxicol Sci       Date:  2018-02-01       Impact factor: 4.849

Review 4.  Idiosyncratic drug-induced liver injury: a clinical update.

Authors:  Haripriya Maddur; Naga Chalasani
Journal:  Curr Gastroenterol Rep       Date:  2011-02

Review 5.  Role of biotransformation studies in minimizing metabolism-related liabilities in drug discovery.

Authors:  Yue-Zhong Shu; Benjamin M Johnson; Tian J Yang
Journal:  AAPS J       Date:  2008-03-13       Impact factor: 4.009

6.  Evaluation of DILI Predictive Hypotheses in Early Drug Development.

Authors:  Rosa Chan; Leslie Z Benet
Journal:  Chem Res Toxicol       Date:  2017-03-15       Impact factor: 3.739

Review 7.  Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib.

Authors:  Han Kiat Ho; James Chun Yip Chan; Klarissa D Hardy; Eric Chun Yong Chan
Journal:  Drug Metab Rev       Date:  2015-02-02       Impact factor: 4.518

Review 8.  In vitro testing for diagnosis of idiosyncratic adverse drug reactions: Implications for pathophysiology.

Authors:  Abdelbaset A Elzagallaai; Michael J Rieder
Journal:  Br J Clin Pharmacol       Date:  2015-06-01       Impact factor: 4.335

Review 9.  Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.

Authors:  Brian A Baldo; Nghia H Pham
Journal:  Cancer Metastasis Rev       Date:  2013-12       Impact factor: 9.264

10.  Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.

Authors:  Naga Chalasani; Robert J Fontana; Herbert L Bonkovsky; Paul B Watkins; Timothy Davern; Jose Serrano; Hongqiu Yang; James Rochon
Journal:  Gastroenterology       Date:  2008-09-17       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.